Published in Endocr Rev on December 01, 1993
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) | NCT03512262
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest (1999) 3.60
Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest (2001) 3.37
Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol (2001) 2.23
Current and potential future drug treatments for osteoporosis. Ann Rheum Dis (1996) 2.21
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A (1996) 1.61
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest (2000) 1.34
T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab (2008) 1.28
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One (2009) 1.20
Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. Endocrinology (2008) 1.06
Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab (2010) 1.03
Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo. Am J Pathol (2007) 1.01
Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J Biol Chem (2007) 0.98
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol (2004) 0.97
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
The rachitic tooth. Endocr Rev (2013) 0.96
Prevention and treatment of multiple osteoporotic compression fracture. Asian Spine J (2014) 0.95
Anabolic agents and bone quality. Clin Orthop Relat Res (2011) 0.94
Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes. PLoS One (2012) 0.93
Gap junction intercellular communication: a review of a potential platform to modulate craniofacial tissue engineering. J Biomed Mater Res B Appl Biomater (2009) 0.93
Fasting plasma glucose levels are related to bone mineral density in postmenopausal women with primary hyperparathyroidism. Int J Clin Exp Med (2008) 0.92
Osteoanabolics. Indian J Endocrinol Metab (2012) 0.92
A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int (2006) 0.92
Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial. Osteoporos Int (2011) 0.92
Multiple calcium channel transcripts in rat osteosarcoma cells: selective activation of alpha 1D isoform by parathyroid hormone. Proc Natl Acad Sci U S A (1995) 0.91
Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol (2012) 0.91
Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway. J Biol Chem (2011) 0.91
Alternating release of different bioactive molecules from a complexation polymer system. Biomaterials (2008) 0.90
The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J Cell Biochem (2009) 0.89
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One (2010) 0.89
Heparin-insensitive calcium release from intracellular stores triggered by the recombinant human parathyroid hormone receptor. Br J Pharmacol (1995) 0.88
Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis (2009) 0.88
The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab (2012) 0.87
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis. Int J Womens Health (2010) 0.86
Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem (2008) 0.86
Pulsatile release of parathyroid hormone from an implantable delivery system. Biomaterials (2007) 0.85
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone. Curr Mol Pharmacol (2012) 0.84
Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Iowa Orthop J (1999) 0.84
Spatial regulation of controlled bioactive factor delivery for bone tissue engineering. Adv Drug Deliv Rev (2014) 0.83
Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging (2007) 0.83
New concepts in calcium-sensing receptor pharmacology and signalling. Br J Pharmacol (2012) 0.83
A roadmap to the brittle bones of cystic fibrosis. J Osteoporos (2010) 0.83
Urinary calcium and oxalate excretion in healthy adult cats are not affected by increasing dietary levels of bone meal in a canned diet. PLoS One (2013) 0.82
Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int (2013) 0.81
Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model. Osteoporos Int (2006) 0.80
N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action. J Bone Miner Res (2015) 0.80
T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Ann N Y Acad Sci (2015) 0.79
Stemming bone loss by suppressing apoptosis. J Clin Invest (1999) 0.79
Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells. J Bone Miner Metab (2005) 0.79
Use of Teriparatide to improve fracture healing: What is the evidence? World J Orthop (2015) 0.79
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporos Int (2012) 0.78
Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J Am Aging Assoc (2002) 0.78
Osteoblasts in bone physiology-mini review. Rambam Maimonides Med J (2012) 0.78
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J Bone Miner Metab (2005) 0.77
Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone. Bone Res (2014) 0.77
Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin. AAPS PharmSci (2001) 0.76
Additive Effects of Mechanical Marrow Ablation and PTH Treatment on de Novo Bone Formation in Mature Adult Rats. Cells (2012) 0.76
Structural features of parathyroid hormone receptor coupled to Galpha(s)-protein. Biophys J (2006) 0.76
Stimulation of creatine kinase activity in rat skeletal tissue in vivo and in vitro by protease-resistant variants of parathyroid hormone fragments. Biochem J (1995) 0.75
Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone. Bone Rep (2016) 0.75
Intermittent administration of parathyroid hormone improves the repairing process of rat calvaria defects: A histomorphometric and radiodensitometric study. Med Oral Patol Oral Cir Bucal (2015) 0.75
Intermittent parathyroid hormone (PTH) promotes cementogenesis and alleviates the catabolic effects of mechanical strain in cementoblasts. BMC Cell Biol (2017) 0.75
Preprogrammed Long-Term Systemic Pulsatile Delivery of Parathyroid Hormone to Strengthen Bone. Adv Healthc Mater (2016) 0.75
CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone. Front Endocrinol (Lausanne) (2017) 0.75
Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold. Biomaterials (2016) 0.75
Feasibility and Efficacy of Autologous Bone Marrow Aspirate Transplantation Combined with Human Parathyroid Hormone 1-34 Administration to Treat Osteonecrosis in a Rabbit Model. Bone Marrow Res (2017) 0.75
Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. BMC Musculoskelet Disord (2017) 0.75
Effect of TheraCyte-encapsulated parathyroid cells on lumbar fusion in a rat model. Eur Spine J (2012) 0.75
Modeling and remodeling effects of intermittent administration of teriparatide (parathyroid hormone 1-34) on bone morphogenetic protein-induced bone in a rat spinal fusion model. Bone Rep (2016) 0.75
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet (1976) 4.24
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr (1998) 2.37
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Prevention of spinal osteoporosis in oophorectomised women. Lancet (1980) 2.34
Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci (1983) 2.18
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res (1997) 1.98
Fracture history and bone loss in patients with MS. Neurology (1998) 1.97
Pathogenesis of osteoporosis. Lancet (1993) 1.93
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Importance of precision in bone density measurements. J Clin Densitom (2001) 1.82
The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol (1984) 1.80
Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J (1973) 1.79
Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol (2003) 1.74
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
Chloramphenicol-induced changes in the synthesis of ribosomal, transfer, and messenger ribonucleic acids in Escherichia coli B/r. J Bacteriol (1977) 1.62
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology (1994) 1.54
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53
Progeston therapy for menstrually related aphthae. Int J Oral Surg (1978) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med (1978) 1.50
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int (2008) 1.44
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone (2007) 1.43
Exogenous calciferol (vitamin D) and vitamin D endocrine status among elderly nursing home residents in the New York City area. J Am Geriatr Soc (1993) 1.42
Constant mineralization density distribution in cancellous human bone. Bone (2003) 1.41
Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab (1996) 1.41
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology (2001) 1.41
Bone response to termination of oestrogen treatment. Lancet (1978) 1.38
The redistribution of body sodium in women on long-term oestrogen therapy. Clin Sci Mol Med (1974) 1.38
Interaction of calcium nutrition and physical activity on bone mass in young women. J Bone Miner Res (1988) 1.37
Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol (1985) 1.37
Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res (1997) 1.36
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia (2009) 1.31
Milk and bones. BMJ (1994) 1.27
Elementary schoolteachers' understanding of diabetes. Diabetes Educ (1987) 1.27
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27
Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med (1998) 1.25
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol (2001) 1.24
Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J (1980) 1.24
Quantitation of Ca ATPase, feet and mitochondria in superfast muscle fibres from the toadfish, Opsanus tau. J Muscle Res Cell Motil (1991) 1.24
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res (1992) 1.23
Prevention of osteoporosis. Clin Orthop Relat Res (1987) 1.22
Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab (1986) 1.18
Rate of ribosomal ribonucleic acid chain elongation in Escherichia coli B/r during chloramphenicol treatment. J Bacteriol (1977) 1.18
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. Br Med J (1973) 1.17
Stability of ribosomal and transfer ribonucleic acid in Escherichia coli B/r after treatment with ethylenedinitrilotetraacetic acid and rifampicin. J Bacteriol (1975) 1.17
Effect of Na, metabolic inhibitors and ATP on Ca movements in L cells. J Physiol (1971) 1.16
Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst (1989) 1.15
Bone mass and body composition in normal women. J Bone Miner Res (1992) 1.13
The anabolic effects of parathyroid hormone. Osteoporos Int (2002) 1.13
Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res (1995) 1.12
Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med (1993) 1.11
Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab (1993) 1.10
Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res (1996) 1.09
A comparison of two laser-based methods for determination of burn scar perfusion: laser Doppler versus laser speckle imaging. Burns (2005) 1.08
Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int (1997) 1.08
Fluoride and bone--quantity versus quality. N Engl J Med (1990) 1.08
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. Health Technol Assess (2010) 1.06
Migration of axonal protein: absence of a protein concentration gradient and effect of inhibition of protein synthesis. Exp Brain Res (1967) 1.05
The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ (1996) 1.05
Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res (2001) 1.05
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry (2001) 1.04